The Current Ratio as of December 2024 (TTM) for Immunovant, Inc. (IMVT) is 7.61

According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.61. This represents a change of -46.14% compared to the average of 14.13 of the last 4 quarters.

Immunovant, Inc. (IMVT) Historical Current Ratio (quarterly & annually)

How has IMVT Current Ratio performed in the past?

The mean historical Current Ratio of Immunovant, Inc. over the last ten years is 9.20. The current 7.61 Current Ratio has changed 8.18% with respect to the historical average. Over the past ten years (40 quarters), IMVT's Current Ratio was at its highest in in the September 2020 quarter at 35.15. The Current Ratio was at its lowest in in the June 2018 quarter at 0.

Immunovant, Inc. (IMVT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Immunovant, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immunovant, Inc. (IMVT) Average Current Ratio

How has IMVT Current Ratio performed in the past?

The current Current Ratio of Immunovant, Inc. (IMVT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Immunovant, Inc. (IMVT) Current Ratio vs. Peers

How is IMVT’s Current Ratio compared to its peers?

Immunovant, Inc.’s Current Ratio is greater than Arbutus Biopharma Corporation (7.02), greater than Arcutis Biotherapeutics, Inc. (2.46), greater than Legend Biotech Corporation (4.98), less than Protagonist Therapeutics, Inc. (10.70), less than IVERIC bio, Inc. (0), less than Akero Therapeutics, Inc. (18.63), less than Madrigal Pharmaceuticals, Inc. (17.25), greater than Apellis Pharmaceuticals, Inc. (5.98), greater than 89bio, Inc. (4.36), less than Pliant Therapeutics, Inc. (11.66), less than Arcellx, Inc. (10.26), greater than Stoke Therapeutics, Inc. (4.29), greater than Blueprint Medicines Corporation (5.09), greater than Amylyx Pharmaceuticals, Inc. (3.32), greater than Karuna Therapeutics, Inc. (4.55), less than Day One Biopharmaceuticals, Inc. (19.31), less than null (14.62),

Build a custom stock screener for Immunovant, Inc. (IMVT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunovant, Inc. (IMVT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.